Last updated on August 2018

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)


Brief description of study

To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)

Detailed Study Description

330 Patients who have completed at least one year of treatment with aflibercept will be randomized to two different aflibercept regimens and followed for 76 weeks.

Clinical Study Identifier: NCT02540954

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Clinique medicale de l'oeil de l'Estrie
Sherbrooke, QC Canada
  Connect »

Bayer Clinical Trials Contact

L'Hospitalet de Llobregat, Spain
  Connect »

Bayer Clinical Trials Contact

Southampton, United Kingdom
  Connect »

Bayer Clinical Trials Contact

Great Yarmouth, United Kingdom
  Connect »

Bayer Clinical Trials Contact

Newcastle Upon Tyne, United Kingdom
  Connect »

Bayer Clinical Trials Contact

Middlesborough, United Kingdom
  Connect »